Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P00750 (PLA)
 16,800 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A new poly(L-lactide) (PLA)-degrading actinomycete, Kibdelosporangium aridum, degraded more than 97 mg out of 100 mg added high molecular weight PLA film (Mn: 3.4 x 10(5)) within 14 d in liquid culture. L-Lactic acid, the monomeric degradation product of PLA, was totally assimilated by the strain. In solid culture, many distinct grooves formed by the morphology of filamentous microorganisms on the surface of a PLA film were observed by scanning electron microscopy.
 ...
PMID:Poly(L-lactide) degradation by Kibdelosporangium aridum. 1471 19

Paclitaxel and poly (L-Lactic acid) (PLA) were co-precipitated to form micro and submicron particles in a manner similar to that used in the supercritical antisolvent with enhanced mass transfer (SAS-EM) process. As compared with conventional processes, a major advantage of supercritical CO(2) as an antisolvent in the SAS-EM process is the effective removal of residual organic solvents. In this work, the organic phase was sprayed into supercritical CO(2) (for CO(2), Tc=31.1 degrees C, Pc=73.8 bar) from a 500 microm ID capillary nozzle. Ultrasonic vibration with an amplitude of 0 to 120 microm (from a 3/8'' tip diameter titanium probe) was employed in the high pressure vessel during the antisolvent process to provide enhanced mixing between the solvent and antisolvent phases. The role and effects of ultrasonication on the properties of the resulting particles were studied. When no ultrasonication was applied, micrometer-sized particles were obtained. When ultrasonication was applied, more uniform particles in the submicron size range were obtained. The size of the particles was found to vary with the ultrasonic vibration amplitude. Encapsulation efficiencies up to 83.5% and controlled release of paclitaxel for more than 30 days were achieved with the particles fabricated in this study.
 ...
PMID:Supercritical antisolvent production of biodegradable micro- and nanoparticles for controlled delivery of paclitaxel. 1805 7

Several approaches may be used for hip replacement surgery either in combination with conventional total hip arthroplasty (THA) or resurfacing hip arthroplasty (RHA). This study investigates the differences in hip loading during gait one year or more after surgery in three cohorts presenting different surgical procedures, more specific RHA placed using the direct lateral (RHA-DLA, n=8) and posterolateral (RHA-PLA, n=14) approach as well as THA placed using the direct anterior (THA-DAA, n=12) approach. For the DAA and control subjects, hip loading was also evaluated during stair ascent and descent to evaluate whether these motions can better discriminate between patients and controls compared to gait. Musculoskeletal modelling in OpenSim was used to calculate in vivo joint loading. Results showed that for all operated patients, regardless the surgical procedure, hip loading was decreased compared to control subjects, while no differences were found between patient groups. This indicates that THA via DAA results in similar hip loading as a RHA via DLA or PLA. Stair climbing did not result in more distinct differences in hip contact force magnitude between patients and controls, although differences in orientation were more distinct. However, patients after hip surgery did adjust their motion pattern to decrease the magnitude of loading on the hip joint compared to control subjects.
...
PMID:Does surgical approach or prosthesis type affect hip joint loading one year after surgery? 2700 36

Herein we demonstrate the formation of stereocomplex prodrugs of oligo(l-lactic acid) n-gemcitabine (o(LLA) n-GEM) and oligo(d-lactic acid) n-gemcitabine (o(DLA) n-GEM) for stable incorporation in poly(ethylene glycol)- block-poly(d,l-lactic acid) (PEG- b-PLA) micelles. O(LLA) n or o(DLA) n was attached at the amino group (4-( N)) of GEM via an amide linkage. When n = 10, a 1:1 mixture of o(LLA)10-GEM and o(DLA)10-GEM (o(L+DLA)10-GEM) was able to form a stereocomplex with a distinctive crystalline pattern. Degradation of o(L+DLA)10-GEM was driven by both backbiting conversion and esterase contribution, generating primarily o(L+DLA)1-GEM and GEM. O(L+DLA)10-GEM stably loaded in PEG- b-PLA micelles in the size range of 140-200 nm with an unexpected elongated morphology. The resulting micelles showed improved physical stability in aqueous media and inhibited backbiting conversion of o(L+DLA)10-GEM within micelles. Release of o(L+DLA)10-GEM from micelles was relatively slow, with a t1/2 at ca. 60 h. Furthermore, weekly administration of o(L+DLA)10-GEM micelles i.v. displayed potent antitumor activity in an A549 human non-small-cell lung carcinoma xenograft model. Thus, stereocomplexation of isotactic o(LLA) n and o(DLA) n acts as a potential prodrug strategy for improved stability and sustained drug release in PEG- b-PLA micelles.
 ...
PMID:Stereocomplex Prodrugs of Oligo(lactic acid) n-Gemcitabine in Poly(ethylene glycol)- block-poly(d,l-lactic acid) Micelles for Improved Physical Stability and Enhanced Antitumor Efficacy. 2995 34